Leading the way for those left behind in pain


At Tremeau, we focus on patient populations whose pain management needs are not well-satisfied by the current standard of care. Our unique approach to acute and chronic pain in select conditions is rooted in the mechanism of action, documented efficacy in painful inflammatory conditions, and clinically differentiated profile of COX-2 selective NSAIDs.

Tremeau believes that the multiple, often industry-independent, scientific evaluations of the past 15+ years strongly suggest a re-examination of the potential utility of rofecoxib and etoricoxib. This is especially true with indications in which a COX-2 selective NSAID may provide therapeutic advantages over other standards of care, such as opioids.